AbioCor
   HOME

TheInfoList



OR:

AbioCor was a total
artificial heart An artificial heart is a artificial organ, device that replaces the human heart, heart. Artificial hearts are typically used as a bridge to heart transplantation, but ongoing research aims to develop a device that could permanently replace the ...
(TAH) developed by the
Massachusetts Massachusetts ( ; ), officially the Commonwealth of Massachusetts, is a U.S. state, state in the New England region of the Northeastern United States. It borders the Atlantic Ocean and the Gulf of Maine to its east, Connecticut and Rhode ...
-based company
AbioMed Abiomed, Inc. is a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment. Abiomed develops and manufactures temporary external and implantable mechanical circulatory support devices. ...
. It was fully implantable within a patient, due to a combination of advances in miniaturization, biosensors,
plastics Plastics are a wide range of synthetic or semisynthetic materials composed primarily of polymers. Their defining characteristic, plasticity, allows them to be molded, extruded, or pressed into a diverse range of solid forms. This adaptab ...
and energy transfer. The AbioCor ran on a rechargeable source of power. The internal battery was charged by a transcutaneous energy transmission (TET) system, meaning that no wires or tubes penetrated the skin, reducing the risk of infection. However, because of its size, this heart was only compatible with men who had a large frame. It had a product life expectancy of 18 months. AbioCor was surgically introduced into 15 total patients, 14 of them during a clinical trial and one after FDA approval. However, due to insufficient evidence of its efficacy, AbioMed abandoned further development of the product.


History

AbioMed was founded by Param Singh and David Lederman. The company began development of the AbioCor device in the 1990s, beginning animal studies in 1998 in preparation to demonstrate readiness for formal clinical trials in humans. On January 30, 2001, the FDA granted AbioMed an investigational device exemption (IDE) for implantation into humans via a clinical trial. This opened the door for the first implantation of the AbioCor into
Robert Tools Robert L. Tools (July 31, 1942 – November 30, 2001) was the world's first recipient of a fully self-contained artificial heart, called AbioCor. The operation took place on July 2, 2001. He survived for 151 days without a living heart. Dr. ...
on July 2, 2001. He lived for 151 days before having a fatal
cerebrovascular accident Stroke is a medical condition in which poor blood flow to a part of the brain causes cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. Both cause parts of the brain to stop ...
. ''Time'' magazine awarded the AbioCor its Invention of the Year award in late 2001. The second patient, Tom Christerson, who was given less than a 20 percent chance of surviving 30 days at the time of his surgery, lived for 512 days after receiving the AbioCor, dying on February 7, 2003, due to the wearing out of an internal membrane of the AbioCor. An additional 12 patients had the device implanted into 2004, resulting in an average life span of less than five months among all 14 patients. In some cases the device extended survival by several months, allowing the patients to spend valuable time with family and friends. In two cases, the device extended survival by 10 and 17 months respectively, and one patient was discharged from the hospital to go home. For a patient to be eligible for implantation with the AbioCor, the person must have had severe
heart failure Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome caused by an impairment in the heart's ability to Cardiac cycle, fill with and pump blood. Although symptoms vary based on which side of the heart is affected, HF ...
(with failure of both ventricles) and had to be likely to die within two weeks without transplantation. Though the device was initially rejected by FDA Circulatory System Devices Panel in 2005 for
Humanitarian Device Exemption A Humanitarian Device Exemption is an approval process provided by the United States Food and Drug Administration allowing a medical device to be marketed without requiring evidence of effectiveness. Generally, these are known as orphan devices. T ...
(HDE) status, it was eventually approved by the
Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...
on September 5, 2006, for HDE status. However, only one patient received the AbioCor after approval, a "76-year-old man with congestive heart failure, who did not qualify for a heart transplant." In August 2012, key AbioCor researcher and developer David Lederman died from pancreatic cancer. The company also had plans to improve the AbioCor with a second version based upon the AbioCor ventricles and the
Penn State #Redirect Pennsylvania State University The Pennsylvania State University (Penn State or PSU) is a Public university, public Commonwealth System of Higher Education, state-related Land-grant university, land-grant research university with ca ...
energy converter. It was expected to last for five years, more than triple the life expectancy of AbioCor. The company stated it would be 30 percent smaller than the original model, and it could be implanted in smaller men and women. Additional modifications were planned to reduce the patient's risk of stroke, which was a concern of the FDA. , AbioCor II has not come to fruition, however. Additionally, the AbioCor product has been removed from the AbioMed website, with several news agencies reporting in 2015 that the company had quietly abandoned further development of the device. In 2019, Abiomed was marketing the Impella Ventricular Support Systems, left-side heart pump models "intended to help pump blood in patients who need short-term support (up to 6 days)".


In popular culture

The AbioCor heart is featured in the 2009 film '' Crank: High Voltage'', when it is transplanted into the main character Chev Chelios's (
Jason Statham Jason Statham ( ; born 26 July 1967) is an English actor. He is known for portraying tough, gritty, or violent characters in various action thriller films, and has been credited for leading the resurgence of action films during the 2000s and 2 ...
) chest after he had been abducted by Chinese mobsters in the very beginning of the movie. However, the heart depicted in the film has a much lower battery life but gives Chev
superhuman The term superhuman refers to humans, humanoids or other beings with abilities and other qualities that exceed those naturally found in humans. These qualities may be acquired through natural ability, self-actualization or technological aids. ...
athleticism when fully charged (for dramatic purposes). The model of the heart in the movie is called AviCor.


See also

* Gus Rosenberg


References


External links


AbioMed FAQ
(PDF)

{{DEFAULTSORT:Abiocor Cardiology Implants (medicine) Inventions in the Smithsonian Institution Prosthetics